Frequency of biologic switching and the outcomes of switching in children and young people with juvenile idiopathic arthritis: a national cohort study

Lianne Kearsley-Fleet, Eleanor Heaf, Rebecca Davies, Eileen Baildam, Michael W Beresford, Helen E Foster, Taunton R Southwood, Wendy Thomson, Kimme L Hyrich, on behalf of the BCRD and BSPAR-ETN study groups

Summary

Background Information is scarce about biological disease-modifying antirheumatic drug (DMARD) switching patterns in children and young people (aged ≤16 years) with juvenile idiopathic arthritis in an era of many biologic therapies. The best choice of biologic to use if the first biological DMARD is not beneficial also remains unclear. We aimed to quantify and characterise biologic switching patterns in children and young people with juvenile idiopathic arthritis, and to compare the effectiveness of using a second tumour necrosis factor inhibitor (TNFi) versus non-TNFi is following failure of a first TNFi biologic in routine clinical practice.

Methods Our study population comprised patients with juvenile idiopathic arthritis who were enrolled in two parallel UK cohort studies (the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study [BSPAR-ETN] and the Biologics for Children with Rheumatic Diseases [BCRD] study) between Jan 1, 2004, and April 11, 2019. Data on disease characteristics and DMARD therapy were collected at the time of initiation of a first biologic, at 6 months, at 1 year, and annually thereafter. Biologic switching patterns were described in all patients who started their first biologic from Jan 1, 2010, onwards. Among patients who started treatment with their first biologic from Jan 1, 2004, onwards, had polyarticular course juvenile idiopathic arthritis (extended oligoarthritis or polyarthritis [positive or negative for rheumatoid factor]), and who had started a second biologic, we assessed changes in outcome variables at 6 months compared with baseline and compared the proportion of patients who achieved an American College of Rheumatology Pediatric (ACR Pedi) 90 response and minimal disease activity at 6 months on the basis of the class of the second biologic (a second TNFi vs non-TNFi biologic). Changes in outcome variables at 6 months were compared using linear regression or logistic regression, adjusted for propensity quintiles to account for confounding by indication. We used multiple imputation to account for missing data.

Findings Between Jan 1, 2004, and April 11, 2019, 2361 patients were enrolled on initiation of biologic therapy. From Jan 1, 2010, onwards, 1152 patients started their first biologic, most of whom started treatment with TNFIs (1050 [91%]). The median follow-up was 2-2 years (IQR 1-3-8). During this time, 270 (23%) of 1152 patients started a second biologic, 61 (5%) started a third biologic, and 11 (1%) started a fourth biologic. Among 240 patients with polyarticular-course juvenile idiopathic arthritis, 194 (81%) started a second TNFi and 46 (19%) started a non-TNFi after an initial TNFi had failed. Choice of second treatment (second TNFi vs non-TNFi biologic) did not affect the proportion of patients who achieved an ACR Pedi 90 response (adjusted odds ratio [OR] 2-5, 95% CI 0-8-7-9; p=0.11) or minimal disease activity (adjusted OR 1-6, 95% CI 0-6-3-8; p=0.33).

Interpretation For many children and young people with juvenile idiopathic arthritis, treatment with a first or second biologic is not beneficial. We found no evidence that switching to a second non-TNFi biologic was more beneficial than a second TNFi.

Funding Versus Arthritis and The British Society for Rheumatology.

Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.

Introduction

Biological disease-modifying antirheumatic drugs (DMARDs), or biologics, have become a main treatment option in juvenile idiopathic arthritis, particularly for individuals who do not respond to, or are intolerant of the conventional synthetic DMARDs, such as methotrexate. The introduction of biological DMARDs has improved patient outcomes, and many more children now reach adulthood without substantial joint damage or complications from persistent uveitis compared with the pre-biologic era.1,2 Tumour necrosis factor inhibitors (TNFIs), such as etanercept and adalimumab, remain the most commonly prescribed biologics for juvenile idiopathic arthritis.3 However, several other classes of biological DMARDs are now available, including the T-cell co-stimulatory modulator abatacept, the interleukin (IL)-6 pathway inhibitor tocilizumab, IL-1 inhibitors (including the IL-1 receptor antagonist anakinra and IL-1β inhibitor
21% received at least three different biological drugs, often received at least three different classes of biologic, and rheumatoid arthritis suggested that at least 6% of patients are on multiple biologics. A 2018 publication about adults with rheumatoid arthritis, who are recommended to start TNFis, or individuals with macrophage activation syndrome non-responsive to corticosteroids, who were recommended to initiate treatment with anakinra. After methotrexate, the majority of children with juvenile idiopathic arthritis should start an initial TNFi, except those with systemic juvenile idiopathic arthritis, who are recommended to start tocilizumab. After an initial biologic is ineffective, patients with systemic juvenile idiopathic arthritis can switch to anakinra, whereas all other patients are recommended to start a second TNFi, with the exception of patients who are positive for rheumatoid factor, who are recommended to start rituximab.

With the increasing availability of other biologic classes, the proportion of children and young people with juvenile idiopathic arthritis who are switching between biologics remains unclear. A better understanding of patients with juvenile idiopathic arthritis who switch biologic drugs multiple times is vital to better inform future treatment guidelines and health economic evaluations. Additionally, although it is recognised that children are switching between biologics, no data are available to inform prescribing after patients do not respond to treatment with a first biologic, usually a TNFi. As a result of the paucity of real-world evidence, at present two conflicting recommendations exist for patients when switching to a second biologic due to ineffectiveness of an initial TNFi: 2015 NHS England guidelines and the 2019 American College of Rheumatology guidelines, which recommend that patients switch to an alternative class of biologic (eg, tocilizumab or abatacept). Repeat analysis with a larger sample size is required to validate these findings. These data will be used to inform practice guidelines, cost-effectiveness, and policy guidelines.
(ACR) guidelines\textsuperscript{10} suggest treatment with a different class of biologic. The use of real-world data to identify the optimum choice of second biologic is methodologically challenging because of the potential of confounding by indication; patients might be prescribed a certain biological therapy due to their characteristics (ie, systemic features, disease severity), and thus comparing the treatments might be confounded by these characteristics. Therefore, careful statistical approaches must be considered.

In this study, we aimed to quantify the proportion of children and young people with juvenile idiopathic arthritis who initiated treatment with a first biologic from Jan 1, 2010, onwards (n=1055).

Figure 1: Biologic switching in patients with juvenile idiopathic arthritis (excluding systemic juvenile idiopathic arthritis) who initiated treatment with a first biologic from Jan 1, 2010, onwards (n=1055)

TNFi=tumour necrosis factor inhibitor. IL=interleukin.
arthritis starting a first biologic who subsequently switch biologic therapy, the extent of multiple switching, and with what pattern switching occurs. We also aimed to compare the effectiveness of different classes of biologics after switching from a first TNFi in routine clinical practice.

**Methods**

**Study design and participants**

We analysed data from two ongoing national biologic cohort studies of children and young people with juvenile idiopathic arthritis in the UK: the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study (BSPAR-ETN), established 2004, and the Biologics for Children with Rheumatic Diseases (BCRD) study, established in 2010. Both studies use identical methodology, and patients can be switched between cohorts on the basis of the biologics received. Patients are tracked through the two studies to ensure all data can be combined and analysed for each unique patient.

Children and young people (aged <16 years) with physician-diagnosed juvenile idiopathic arthritis, classified according to the International League of Associations for Rheumatology (ILAR) criteria\(^1\) are eligible for inclusion in the studies and are recruited at the start of biologic therapy. Patients were not required to be biologic naïve. We included all children and young people enrolled into BCRD or BSPAR-ETN between Jan 1, 2004, and April 11, 2019.

All participants or their legal guardians provided written informed consent in accordance with the Declaration of Helsinki. BSPAR-ETN was approved by the West Midlands Research Ethics Committee and BCRD was approved by the North West 7 REC Greater Manchester Central Ethics Committee.

**Procedures**

Baseline data were collected at the start of biological therapy, including patient demographics (age, gender-identity), ILAR category, disease activity including active joint count (ie, swelling not caused by bony enlargement), limited joint count (limited range of motion plus tenderness, pain, or heat), physician’s global assessment of overall disease activity (assessed using a visual analogue scale [0–10 cm]), patient (or parent) global assessment of overall wellbeing (PtGE; assessed using a visual analogue scale [0–10 cm]), functional ability (assessed using the Childhood Health Assessment Questionnaire [CHAQ]), previous and current conventional synthetic therapy, and history of uveitis. Follow-up data were obtained from patient medical records by the prescribing team and transferred to the study database via online web system at 6 months, 1 year, and annually thereafter, and included changes to disease activity, changes to antirheumatic therapies (including start dates, stop dates, and reasons for cessation of therapy), and adverse events. For patients who switched biologic therapy, an additional form was used to collect data on disease activity at the time of switch and 6 months after switching.

**Statistical analysis**

We split the data analysis into two parts: assessment of biologic switching patterns in all children who started their first biologic from Jan 1, 2010, and assessment of response to a second biologic, in all children who started their first biologic from Jan 1, 2004.

---

Figure 2: Biologic switching in patients with systemic juvenile idiopathic arthritis who started treatment with a first biologic from Jan 1, 2010, onwards (n=97)

TNFi=tumour necrosis factor inhibitor. IL=interleukin.
All children who initiated treatment with their first biologic from Jan 1, 2010, onwards, were included in the first part of the analysis. We used this date for two reasons: children starting non-etanercept biologics as their first biologic were only recruited from 2010 (before 2010, the studies were limited to children starting etanercept only), and a previous analysis based on these cohorts\(^1\) has shown that the pattern of biologic prescribing has changed over time, not only with regard to the choice of biologic, with a shift towards more non-etanercept biologics for children with certain disease features (ie, those with uveitis, or systemic juvenile idiopathic arthritis), but also towards earlier use of biologics. Thus, this date is more reflective of current biologic prescribing in patients with juvenile idiopathic arthritis. Patients were censored on the date of last study follow-up, date of death, or April 11, 2019 (data analysis cutoff), whichever came first. We calculated the proportion of patients who switched biologics at least once, and median time from initiation of first biologic to the initiation of a second, third, and fourth biologic. All biologics currently available for the treatment of inflammatory arthritis in children and adults were included, regardless of whether they were licensed specifically for juvenile idiopathic arthritis. Patterns of biologic switching were also stratified by whether patients had systemic juvenile idiopathic arthritis.

For the second part of the analysis, we included all children who initiated treatment with their first biologic from Jan 1, 2004, onwards, and had polyarticular juvenile idiopathic arthritis (extended oligoarthritis or polyarthritis [positive or negative for rheumatoid factor]) with no active uveitis at the time of initiation of their second biologic. We applied the inclusion criterion because we hypothesized that a diagnosis of active uveitis or systemic juvenile idiopathic arthritis would limit the choice of biologic. We used linear regression to assess the proportion of patients who switched biologics at least once, and median time from initiation of first biologic to the initiation of a second, third, and fourth biologic. All biologics currently available for the treatment of inflammatory arthritis in children and adults were included, regardless of whether they were licensed specifically for juvenile idiopathic arthritis. Patterns of biologic switching were also stratified by whether patients had systemic juvenile idiopathic arthritis.

| Second TNFi | Other biologic |
|------------|---------------|
| **Gender** |               |
| Female     | 153 (79%)     | 42 (91%)     |
| Male       | 41 (21%)      | 4 (9%)       |
| **ILAR disease category at initiation of first TNFi** |   |
| Extended oligoarthritis | 64 (33%) | 10 (22%) |
| Polyarthritis (negative for rheumatoid factor) | 98 (51%) | 27 (59%) |
| Polyarthritis (positive for rheumatoid factor) | 32 (16%) | 9 (20%) |
| **First TNFi** |       |
| Etanercept | 158 (81%)     | 30 (65%)     |
| Infliximab | 10 (5%)       | 4 (9%)       |
| Adalimumab | 26 (13%)      | 12 (26%)     |
| **Reason for cessation of first biologic** |               |
| Ineffectiveness | 117 (60%) | 27 (59%) |
| Adverse events (excluding uveitis or intolerance) | 36 (19%) | 7 (15%) |
| Ineffectiveness and intolerance | 23 (12%) | 7 (15%) |
| Patient decision (injection related) | 9 (5%) | 3 (7%) |
| Other | 9 (5%) | 2 (4%) |
| **Time since initiation of first TNFi (years)** | 1·1 (0·5–2·5) | 1·0 (0·7–3·5) |
| **Start year of second biologic** |       |
| Before 2010 | 23 (12%) | 1 (2%) |
| 2010–15 | 77 (40%) | 19 (41%) |
| 2016–19 | 94 (48%) | 26 (57%) |
| **Age at initiation of second biologic (years)** | 12 (9–15) | 12 (9–15) |
| **Disease duration at time of initiation of second biologic (years)** | 4 (2–7)* | 5 (2–8) |
| **Disease duration at time of initiation of second biologic (years)** | 4 (2–7)* | 5 (2–8) |
| **Second biologic** |       |
| Etanercept | 10 (5%) | 0 |
| Infliximab | 70 (36%) | 0 |
| Adalimumab | 114 (59%) | 0 |
| Rituximab | 0 | 6 (13%) |
| Tocilizumab | 0 | 33 (72%) |
| Abatacept | 0 | 6 (13%) |
| Ustekinumab | 0 | 1 (2%) |
| **Concomitant steroids within 2 weeks of initiation of second biologic** | 52/152 (34%) | 7/35 (20%) |
| **Concomitant methotrexate** | 132 (68%) | 30 (65%) |
| **Active joint count (75 joints)** |       |
| Patients with available data | 176 (91%) | 43 (93%) |
| Median (IQR) | 3 (1–6) | 3 (1–9) |
| **Limited joint count (71 joints)** |       |
| Patients with available data | 174 (90%) | 43 (93%) |
| Median (IQR) | 2 (0–6) | 2 (0–5) |
| **Physician’s global assessment of disease activity (0–10 cm VAS)** |       |
| Patients with available data | 131 (68%) | 29 (63%) |
| Median (IQR) | 3 (2–4) | 4 (2–6) |

(Table 1 continues on next page)
compared between patients starting a second TNFi and those switching to an alternative class of biologic using linear regression (for core outcome variables and JADAS-71 score) or logistic regression, adjusting for propensity quintiles to account for confounding by indication.\textsuperscript{16} For the ACR Pedi 90 response and minimal disease activity outcomes, patients who stopped biologic therapy before measurement of the 6-month outcomes were classified as non-responders, with the exception of patients who stopped treatment due to remission (as reported by the clinician) who were classified as responders. We used Kaplan-Meier curves to assess the duration of treatment with a second biologic during the time of 3.7 years (IQR 2.4–5.1) from initiation of the first biologic, 61 (5%) patients started a third biologic after a median time of 1.3 years (IQR 0.6–2.3) from initiation of the first biologic, 61 (5%) patients started a fourth biologic after a median time of 2.5 years (IQR 1.6–3.7) from initiation of the first biologic, 11 (1%) patients started a fifth biologic after a median time of 2.4 years (IQR 1.5–3.8) from initiation of the first biologic, 270 (23%) of 1152 patients started a second biologic following initial TNFi (n=240) and the second was limited to only patients who stopped treatment with their initial TNFi due to ineffectiveness.

We used multiple imputation (83 iterations based on the proportion of incomplete cases\textsuperscript{17}) to account for missing data. We calculated propensity scores and stratified them into quintiles to include as an indicator variable in the regression models. The following variables included in the propensity score were measured at the time of initiation of a second biologic: second biologic start year (before 2010, 2010–15, or 2016–18), time since initiation of first biologic, gender, ILAR category, age, disease duration, concomitant methotrexate, concomitant steroids, active joint count, limited joint count, physician's global assessment, PGE, CHAQ, pain, erythrocyte sedimentation rate, c-reactive protein concentration, and JADAS-71 score.

We used Stata software (version 14.0) for all analyses.

**Role of the funding source**

The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.

**Results**

Between Jan 1, 2004, and April 11, 2019, 2361 patients were enrolled on initiation of biologic therapy. 1152 patients (1055 with juvenile idiopathic arthritis; 97 with systemic juvenile idiopathic arthritis) initiated treatment with their first biologic from Jan 1, 2010, onwards, of whom 1081 (95%; of 1112 patients with available data) reported previous treatment with methotrexate. 1050 (91%) of 1152 patients started initial treatment with a TNFi, although among the 97 patients with systemic juvenile idiopathic arthritis, IL-6 and IL-1 inhibitors were the most common first biologic therapy (55 [57%] patients initiated treatment with the IL-6 inhibitor tocilizumab; 28 [29%] patients initiated treatment with an IL-1 inhibitor). A total of 2988 person-years of observed follow-up was available and the median duration of follow-up per patient was 2.2 years (IQR 1.3–3.8; maximum 9.1 years). During follow-up, 36 (5%) of 1152 patients withdrew or were lost to follow-up and 137 (12%) moved to an adult clinic where data capture from the adult hospital had not yet been established. 270 (23%) of 1152 patients started a second biologic after a median time of 1.3 years (IQR 0.6–2.3) from initiation of the first biologic, 61 (5%) patients started a third biologic after a median time of 2.5 years (IQR 1.6–3.7) from initiation of the first biologic, and 11 (1%) patients started a fourth biologic after a median time of 3.7 years (IQR 2.4–5.1) from initiation of the first biologic.

Of the 270 patients who started a second biologic, 163 (60%) switched due to ineffectiveness and 66 (24%) switched due to adverse events (other reason or data missing for 41 [15%] patients). Of 1055 patients without
systemic juvenile idiopathic arthritis disease, 250 patients started a second biologic. 247 (99%) of these 250 patients had initiated treatment with a first TNFi biologic, of whom 202 (82%) started a second TNFi, whereas 45 (18%) switched from a TNFi to another class of biologic (figure 1). Of the 20 patients with systemic juvenile idiopathic arthritis who started a second biologic, eight (40%) patients started tocilizumab following initial treatment with an IL-1 inhibitor and six (30%) initiated treatment with an IL-1 inhibitor after initial treatment with tocilizumab (figure 2).

Of the 61 patients who started a third biologic, 24 (39%) switched due to repeated ineffectiveness, and 20 (33%) switched due to ineffectiveness and adverse events (other reason or data missing for 17 [28%] patients). Of the 57 patients without systemic juvenile idiopathic arthritis, 33 (58%) started tocilizumab, four (7%) started abatacept, and four (7%) started rituximab following two previous TNFIs, although seven (12%) patients switched to a third TNFi. Four (4%) patients with systemic juvenile idiopathic arthritis started a third biologic, all of which were IL-1 inhibitors.

Of the 11 patients who started a fourth biologic, four (36%) switched due to repeated ineffectiveness and six (55%) switched due to ineffectiveness and adverse events (other reason or data missing for one [9%] patient). Six (55%) of 11 patients started either their third or fourth class of biologic. Of the 270 patients who had been exposed to at least two different biologic therapies, 25 (9%) patients had re-tried a biologic they had previously been treated with.

2361 patients were exposed to biologic therapy since Jan 1, 2004, and thus were eligible for inclusion in the second part of our data analysis (assessment of response to a second biologic). Of these 2361 patients, 817 (35%) patients reported switching to a second biologic, of whom 282 (35%) had polyarticular course juvenile idiopathic arthritis (arthritis extended or polyarticular [positive or negative for rheumatoid factor]) and had outcome data available. 42 of these 282 patients had active uveitis and were excluded. Thus, 240 patients were included in the analysis of response to a second biologic: 194 (81%) of 240 started a second TNFi, and 46 (19%) started an alternative class of biologic (tocilizumab [n=33], abatacept [n=6], rituximab [n=6], and the IL-12 and IL-23 inhibitor ustekinumab [n=1]). Patient characteristics at the initiation of a second biologic were similar between those who were starting treatment with a second TNFi and those switching to another class of biologic (table 1), including the reason for discontinuation of the first biologic.

At 6 months (median follow-up 0.56 years [IQR 0.45–0.75]), no differences were identified with regard to change in individual outcome variables or JADAS-71 score between patients who started a second TNFi and those who initiated treatment with an alternative class of biologic (table 2). Among the 240 patients with polyarticular course juvenile idiopathic arthritis, a total of 22% (95% CI 16–28) of patients achieved an ACR Pedi 90 response, and 29% (23–36) of patients achieved minimal disease activity. No differences were identified in the

| Active joint count (71 joints) | Second TNFi (n=194) | Other biologic (n=46) | p value |
|--------------------------------|---------------------|---------------------|---------|
| Baseline                       | 5 (0.5)             | 5 (0.9)             | 0.77    |
| 6 months                       | 2 (0.3)             | 2 (0.8)             | 0.61    |
| Difference*                    | -2 (0.5)            | -2 (0.1)            | ..      |
| Unadjusted β coefficient (95% CI) | -0.5 (-1.8 to 0.9) | 1 (ref)             | 0.51    |
| Propensity quintile adjusted β coefficient (95% CI) | -0.6 (-2.9 to 1.8) | 1 (ref)             | 0.64    |

| Limited joint count (71 joints) | Second TNFi (n=194) | Other biologic (n=46) | p value |
|---------------------------------|---------------------|---------------------|---------|
| Baseline                        | 4 (0.5)             | 3 (0.8)             | 0.47    |
| 6 months                        | 3 (0.5)             | 2 (0.8)             | 0.43    |
| Difference*                     | -1 (0.6)            | -1 (0.2)            | ..      |
| Unadjusted β coefficient (95% CI) | 0.7 (-1.6 to 2.9)  | 1 (ref)             | 0.55    |
| Propensity quintile adjusted β coefficient (95% CI) | 0.2 (-2.6 to 3.0) | 1 (ref)             | 0.89    |

| Physician’s global assessment of disease activity (VAS 0–10 cm) | Second TNFi (n=194) | Other biologic (n=46) | p value |
|---------------------------------------------------------------|---------------------|---------------------|---------|
| Baseline                                                      | 3 (0.2)             | 3 (0.4)             | 0.11    |
| 6 months                                                      | 1 (0.2)             | 2 (0.4)             | 0.081   |
| Difference*                                                   | -1 (0.2)            | -1 (0.5)            | ..      |
| Unadjusted β coefficient (95% CI)                            | -0.6 (-1.4 to 0.2)  | 1 (ref)             | 0.17    |
| Propensity quintile adjusted β coefficient (95% CI)          | -0.7 (-1.7 to 0.3)  | 1 (ref)             | 0.16    |

| PtGE (VAS 0–10 cm)                                             | Second TNFi (n=194) | Other biologic (n=46) | p value |
|---------------------------------------------------------------|---------------------|---------------------|---------|
| Baseline                                                      | 4 (0.2)             | 4 (0.5)             | 0.43    |
| 6 months                                                      | 2 (0.2)             | 2 (0.4)             | 0.089   |
| Difference*                                                   | -1 (0.2)            | -0.7 (0.6)          | ..      |
| Unadjusted β coefficient (95% CI)                            | -0.8 (-1.8 to 0.2)  | 1 (ref)             | 0.14    |
| Propensity quintile adjusted β coefficient (95% CI)          | -0.8 (-2.1 to 0.4)  | 1 (ref)             | 0.19    |

| CHAQ score (range 0–3)                                        | Second TNFi (n=194) | Other biologic (n=46) | p value |
|---------------------------------------------------------------|---------------------|---------------------|---------|
| Baseline                                                      | 1 (0.0)             | 1 (0.1)             | 0.63    |
| 6 months                                                      | 0 (0.0)             | 0 (0.1)             | 0.40    |
| Difference*                                                   | -0.1 (0.06)         | -0.08 (0.14)        | ..      |
| Unadjusted β coefficient (95% CI)                            | -0.1 (-0.3 to 0.2)  | 1 (ref)             | 0.52    |
| Propensity quintile adjusted β coefficient (95% CI)          | -0.04 (-0.2 to 0.2) | 1 (ref)             | 0.80    |

| Pain (VAS 0–10)                                               | Second TNFi (n=194) | Other biologic (n=46) | p value |
|---------------------------------------------------------------|---------------------|---------------------|---------|
| Baseline                                                      | 4 (0.3)             | 4 (0.5)             | 0.89    |
| 6 months                                                      | 3 (0.6)             | 3 (0.8)             | 0.58    |
| Difference*                                                   | -1.0 (0.3)          | -0.6 (0.6)          | ..      |
| Unadjusted β coefficient (95% CI)                            | -0.3 (-1.4 to 0.7)  | 1 (ref)             | 0.52    |
| Propensity quintile adjusted β coefficient (95% CI)          | -0.4 (-1.7 to 0.8)  | 1 (ref)             | 0.50    |

| Erythrocyte sedimentation rate (mm/h)                         | Second TNFi (n=194) | Other biologic (n=46) | p value |
|---------------------------------------------------------------|---------------------|---------------------|---------|
| Baseline                                                      | 18 (1.7)            | 16 (3.5)            | 0.73    |
| 6 months                                                      | 12 (1.1)            | 9 (2.4)             | 0.21    |
| Difference*                                                   | -5 (1.6)            | -7 (2.7)            | ..      |
| Unadjusted β coefficient (95% CI)                            | 2.7 (-1.8 to 7.2)   | 1 (ref)             | 0.24    |
| Propensity quintile adjusted β coefficient (95% CI)          | 2.4 (-4.8 to 9.7)   | 1 (ref)             | 0.51    |

| C-reactive protein concentration (mg/L)                       | Second TNFi (n=194) | Other biologic (n=46) | p value |
|---------------------------------------------------------------|---------------------|---------------------|---------|
| Baseline                                                      | 14 (2.2)            | 6 (2.2)             | 0.10    |
| 6 months                                                      | 7 (1.3)             | 4 (2.6)             | 0.20    |
| Difference*                                                   | -1.8 (2.0)          | -2.6 (2.7)          | ..      |
| Unadjusted β coefficient (95% CI)                            | 1.2 (-3.2 to 5.7)   | 1 (ref)             | 0.58    |
| Propensity quintile adjusted β coefficient (95% CI)          | -0.9 (-6.6 to 8.4)  | 1 (ref)             | 0.82    |

(Table 2 continues on next page)
Appendix Table 2: 6-month outcomes of patients with polyarticular course juvenile idiopathic arthritis (extended oligoarthritis or polyarthritis [positive or negative for rheumatoid factor]) who started a second biologic (n=240)

| Outcome                        | Second TNFi (n=194) | Other biologic (n=46) | p value |
|--------------------------------|---------------------|-----------------------|---------|
| Proportion of patients who achieved ACR Pedi 90 (%)§ | 24% (12 to 31) | 13% (2 to 25) | 0.68 |
| Unadjusted OR (95% CI)†       | 2.1 (0.7 to 6.2) | 1 (ref) | 0.17 |
| Propensity quintile adjusted OR (95% CI)‡ | 2.5 (0.8 to 7.9) | 1 (ref) | 0.11 |

Date are mean (SE) or %, unless otherwise stated. Multiple imputation (83 datasets) was used to account for missing data. TNFi=tumour necrosis factor inhibitor. VAS=visual analogue scale. PGGe-patient or parent's global assessment of overall wellbeing. CHAQ=Childhood Health Assessment Questionnaire. JADAS-71=Juvenile Arthritis Disease Activity Score assessed in 71 joints. ACR=American College of Rheumatology. ACR Pedi 90=ACR paediatric criteria for 90% improvement. OR=odds ratio. ILAR=International League Against Rheumatism. *From time of initiation of second biologic to 6 months thereafter, accounting for baseline values. †Significant change in variable between baseline and 6 months (p<0.05). §For ACR Pedi 90 and minimal disease activity outcomes, patients who stopped biologic therapy before the 6-month outcome measurements were completed were classified as non-responders and those who stopped because they had achieved remission were classified as responders.

Figure 3: Kaplan-Meier analysis of duration of treatment in patients with polyarticular course juvenile idiopathic arthritis (extended oligoarthritis or polyarthritis [positive or negative for rheumatoid factor]) who started a second biologic (n=240)

Table 2: 6-month outcomes of patients with polyarticular course juvenile idiopathic arthritis (extended oligoarthritis or polyarthritis [positive or negative for rheumatoid factor]) who started a second biologic (n=240)

At 1 year, 63% (95% CI 55–68) of patients remained on their second biologic therapy and at 2 years, 42% (35–49) of patients remained on their second biologic therapy (figure 3). Propensity adjusted Cox-regression identified no significant differences in treatment duration with second biologic between patients on a second TNFi and patients on an alternative class of biologic (p=0.62). By 2 years, 55 (44%) of 124 patients had stopped their second biologic due to ineffectiveness and 17 (14%) due to adverse events, with no differences identified between the two cohorts.

Sensitivity analyses of patients who switched from their first biologic to a second TNFi or tocilizumab, and patients who started a second biologic due to ineffectiveness showed that at 6 months, no differences were identified in individual outcome variables or JADAS-71, or the proportion of patients who achieved ACR Pedi 90 or minimal disease activity between patients who initiated treatment with a second TNFi and those who initiated treatment with an alternative class of biologic in either analysis, adjusted for propensity quintiles (appendix pp 1–4).

Discussion

To our knowledge, this is the first observational study to report on the extent of multibiologic switching in a cohort of children and young people with juvenile idiopathic arthritis, and to compare the effectiveness of different biologics after the failure of a first biologic. Biologic switching was common, with 23% of patients receiving at least two biologics, 5% receiving at least three, and 1% receiving at least four biologics during a median follow-up time of 2–2 years from initiation of their first biologic. However, there was no evidence that among children with polyarticular course juvenile idiopathic arthritis for whom treatment with a first biologic was ineffective, that switching classes of biologic was more beneficial than initiation of treatment with a second biologic within the same class.

Although the majority of patients with juvenile idiopathic arthritis tolerated biologic treatment well and have sustained disease control, some patients do not respond to, or cannot tolerate treatment. Estimating the proportion of patients with juvenile idiopathic arthritis who switch biologics multiple times allows appropriate service development and cost considerations. The use of data from a real-world cohort study is particularly valuable since these findings are representative of national prescribing patterns. The proportion of patients switching to a second biologic in our study was similar to that of a Dutch registry (26%), but the proportion of patients with systemic juvenile idiopathic arthritis who started a second biologic was lower than that in a French retrospective study (44%). The majority of patients recruited in the previous Dutch and French cohort studies started...
treatment with their first biologic before 2010 and therefore might not be representative of current biologic prescribing patterns. Whether a treat-to-target approach was specifically applied in some centres is unknown, thus it is unclear whether outcomes would be different if a specific treat-to-target guideline20,21 was used, but is worth considering in future research whether such an approach was used and whether outcomes improve overall with such an approach. Patients who do not respond to biologic therapy are likely to require increased medical input compared with patients who respond to biologic therapy due to increased frequency of flares and increased need for drug education and monitoring.

In adults with rheumatoid arthritis, evidence supports switching from an initial TNFi to rituximab rather than a second TNFi.22 Evidence also indicates that in patients with exposure to at least one biologic, tocilizumab and a TNFi have similar effectiveness,21 as do rituximab and tocilizumab after initial treatment with a TNFi.23 However, rituximab is not a licensed treatment for children and young people with juvenile idiopathic arthritis and no formal controlled trials of rituximab in juvenile idiopathic arthritis have been done, thus the choice of approved biologics available remains limited. Most patients switch to a second TNFi, with many patients cycling onto their third TNFi despite the availability of alternative biologic therapies. The reasons for these choices are not known but the presence of uveitis might influence the choice of drug in some children.1 At present, two guidelines are available for biologic treatment of children and young people with juvenile idiopathic arthritis and no formal controlled trials of rituximab in juvenile idiopathic arthritis have been done, thus the choice of approved biologics available remains limited. Most patients switch to a second TNFi, whereas ACR10 recommend switching to a non-TNFi (tocilizumab or abatacept). Additionally, the NHS guidelines recommend that patients who are positive for rheumatoid factor should switch to rituximab instead of a TNFi, consistent with adult practice, whereas the ACR guidelines specifically recommend avoidance of this therapy, preferring the use of other classes primarily.

This study is a national cohort study and, although not mandatory, recruitment is recommended for all patients starting a biologic therapy4 and children have been recruited from almost every centre treating children with juvenile idiopathic arthritis in the UK. The study captures longitudinal prospective data from first biologic treatment, with the ability to track biologic switching. The use of robust statistical methods enabled the investigation of multiple outcomes in this analysis. However, juvenile idiopathic arthritis is a relatively rare disease with only 20% of patients estimated to start biologic therapy within the first 3 years after diagnosis,25 with one-fifth of these patients switching to a second biologic. Therefore, this analysis might not be powered to detect smaller differences in outcome, or differences between individual biologic therapies. The sensitivity analysis aimed to remove some of the heterogeneity from the other biologic drug classes, although whether these would be clinically meaningful is unknown. Patient numbers were further limited by the lack of additional core outcome data collected at the time of biologic switch and at 6 months because these forms were not introduced until 2014. A sensitivity analysis limited to patients who started a second biologic due to ineffectiveness of initial TNFi was done, however a similar analysis limited to children who stopped treatment with a first biologic due to an adverse event was not possible due to small patient numbers. Additionally, 42 patients had active uveitis at the time of initiation of their second biologic and thus were excluded, since it was unclear whether these patients were starting the biologic to treat their arthritis or their uveitis. The study did not capture any data on treatment adherence, drug levels, or anti-drug antibody concentrations, which might also influence treatment response. Furthermore, the route or frequency of biologic administration was not investigated, which might have also influenced treatment choice.

The time to initiation of a second biologic was more than 2.5 years after the initiation of a first TNFi in a quarter of children. For a rare disease such as juvenile idiopathic arthritis, it can take time to accumulate enough children for analysis and it is possible that outcomes might differ among children starting their second biologic in 2019, including quicker cycling through biologics. This reduction in time to treatment could in turn have resulted in better overall responses to a second biologic than those observed in the current study, although the proportion of adults with rheumatoid arthritis who respond well to a second biologic is lower than that with a first biologic.22

This is the first observational study to report that approximately one-fifth of children and young people with juvenile idiopathic arthritis in the UK starting their first biologic went on to receive a second biologic, and 5% received at least three biologics. Due to the frequent use of multiple TNFis, it is not possible to identify true multibiologic resistance in juvenile idiopathic arthritis, but the study shows that many children are being treated with multiple biologics. Additionally, among children with polyarticular course juvenile idiopathic arthritis for whom a first biologic was ineffective, no evidence was found to indicate that switching classes of biologic was more beneficial than initiation of treatment with a second biologic within the same class, despite current ACR guidelines.26 Ideally, a randomised trial comparing different second biologics could help address this question with more certainty. Further study of patients requiring multiple biologics is vital to enable patient specific treatment pathways, accurate prognosis discussions, and cost-effectiveness analysis for service provisions. Additional controlled trials of biologic medications are required in juvenile idiopathic arthritis because the number of approved therapeutic options remains small compared with those available for rheumatoid arthritis.
Contributors
EB, MWB, HEF, TRS, WT, and KLH conceptualized and designed the study. LEF, EH, RD, and KLH provided substantial contributions to analysis and interpretation of data. All authors contributed to drafting the article or critically revising the manuscript for important intellectual content, and approved the final version of the article for publication.

Declaration of interests
KLH reports consultancy fees and Honoraria from AbbVie, and grants from UCB, Pfizer, and BMS, outside the submitted work. HEF reports educational research bursaries from Pfizer, Sobi, and AbbVie, and advisory boards from Novartis, Pfizer, and Schering Plough, outside the submitted work. All other authors report no competing interests.

Acknowledgments
We thank the patients, rheumatology and research nurses, and clinicians who have helped support this study, the original British Society for Paediatric and Adolescent Rheumatology (BSPAR) Consensus Group for Prescription of Biologics in Children (established in 2004), the BSPAR Clinical Affairs Committee and the NIHR CRN: Children/Arthritis Research UK Paediatric Rheumatology Clinical Studies Group for their generous support in the establishment of these registers. The recruiting centres were supported by the National Institute for Health Research (NIHR) Clinical Research Network in England. This report includes independent research supported by the NIHR Manchester Biomedical Research Centre. The views expressed in this Article are those of the authors and not necessarily those of the National Health Service, the National Institute for Health Research, or the UK Department of Health. The Biologics for Children with Rheumatic Diseases (BCRD) study is funded by Versus Arthritis (20747). The BSPAR Etanercept cohort study is funded by a research grant to the University of Manchester from the British Society for Rheumatology (BSR). The BSR has previously received restricted income from Pfizer to fund this project. This income finances a wholly separate contract between BSR and the University of Manchester who provide and oversee the data collection, management, and analysis of the data. The principal investigator and her team have full academic freedom and are able to work independently of pharmaceutical industry influence. All decisions concerning analyses, interpretation and publication are made autonomously of any industrial contribution. This study was presented in part at the 2018 British Society for Paediatric and Adolescent Rheumatology Annual Conference, Southampton, UK, Oct 17–18, 2018; the 2018 American College of Rheumatology Annual Meeting, Chicago, IL, USA, May 19–23, 2018; the 2019 British Society for Rheumatology Annual Conference, Birmingham, UK, April 30–May 2, 2019; and the 2019 Annual European Congress of Rheumatology, Madrid, Spain, June 12–15, 2019.

References
1 Ruperto N, Martini A. Current medical treatments for juvenile idiopathic arthritis. Front Pharmacol 2011; 2: 60.
2 Minden K, Niewerth M, Zink A, et al. Long-term outcome of patients with JIA treated with etanercept, results of the biologic register JuMBO. Rheumatology 2012; 51: 1407–15.
3 Kearsley-Fleet L, Davies R, Baldain E, et al. Factors associated with choice of biologic among children with juvenile idiopathic arthritis: results from two UK paediatric biologic registers. Rheumatology 2016; 55: 1556–65.
4 Röning S, Weiss PF, Beukelman T, et al. 2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. Arthritis Rheum 2013; 65: 2499–512.
5 NHS England. Clinical commissioning policy statement: biologic therapies for the treatment of juvenile idiopathic arthritis. 2015. https://www.england.nhs.uk/commissioning/wp-content/uploads/sites/12/2015/10/e03-pl-bio-therapies-jia-oct15.pdf (accessed Jan 23, 2020).
6 Kearsley-Fleet L, Davies R, De Cock D, et al. Biologic refractory disease in rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Ann Rheum Dis 2018; 77: 1405–12.
7 Otten MH, Prince FH, Anirk J, et al. Effectiveness and safety of a second and third biological agent after failing etanercept in juvenile idiopathic arthritis: results from the Dutch National ABC Register. Ann Rheum Dis 2013; 72: 721–7.
8 National Institute for Health and Care Excellence. TA35: guidance on the use of etanercept for the treatment of juvenile idiopathic arthritis. https://www.nice.org.uk/guidance/ta35 (accessed Feb 21, 2020).
9 National Institute for Health and Care Excellence. TA238: tocilizumab for the treatment of systemic juvenile idiopathic arthritis. 2011. https://www.nice.org.uk/guidance/ta238 (accessed Jan 23, 2020).
10 Ringold S, Angeles-Han ST, Beukelman T, et al. 2019 American College of Rheumatology/Arthritis Foundation guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for non-systemic polyarthritis, sacroiliitis, and enthesitis. Arthritis Care Res 2019; 71: 717–34.
11 Davies R, Southwood TR, Kearsley-Fleet L, Lunt M, Hyrich KL. Medically significant infections are increased in patients with juvenile idiopathic arthritis treated with etanercept: Results from the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study. Arthritis Rheumatol 2015; 67: 2487–94.
12 Manners P et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision. J Rheumatol 2004; 31: 1902.
13 Consolaro A, Ruperto N, Bazzo A, et al. Development and validation of a composite disease activity score for juvenile idiopathic arthritis. Arthritis Rheum 2009; 61: 658–66.
14 Giammini EH, Ruperto N, Raveli A, Lovell DJ, Felson DT, Martini A. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997; 40: 1202–09.
15 Magni-Manzoni S, Ruperto N, Pistorio A, et al. Development and validation of a preliminary definition of minimal disease activity in patients with juvenile idiopathic arthritis. Arthritis Rheum 2008; 59: 1120–27.
16 Hade EM, Lu B. Bias associated with using the estimated propensity score as a regression covariate. Stat Med 2014; 33: 74–87.
17 White IR, Royston P, Wood AM. Multiple imputation using chained equations: issues and guidance for practice. Stat Med 2011; 30: 377–99.
18 Romano M, Pontikaki I, Gattinara M, et al. Drug survival and reasons for discontinuation of the first course of biological therapy in 301 juvenile idiopathic arthritis patients. Reumatismo 2014; 65: 278–85.
19 Woerner A, Uttewiller F, Melki J, et al. Biological treatment in systemic juvenile idiopathic arthritis: achievement of inactive disease or clinical remission on a first, second or third biological agent. RMD Open 2015; 1: e000136.
20 Hinze-CHE, Holzinger D, Laikne E, et al. Practice and consensus-based strategies in diagnosing and managing systemic juvenile idiopathic arthritis in Germany. Pediatr Rheumatol Online J 2018; 16: 7.
21 Raveli A, Consolaro A, Horneff G, et al. Treating juvenile idiopathic arthritis to target: recommendations of an international task force. Ann Rheum Dis 2018; 77: 819–28.
22 Soliman MM, Hyrich KL, Lunt M, Watson KD, Symmons DP, Ashcroft DM. Rituximab or a second anti-tumor necrosis factor therapy for rheumatoid arthritis patients who have failed their first anti-tumor necrosis factor therapy? Comparative analysis from the British Society for Rheumatology Biologics Register. Arthritis Care Res (Hoboken) 2012; 64: 1088–15.
23 Lauper K, Nordstrom DC, Pavelka R, et al. Comparative effectiveness of tocilizumab versus TNF inhibitors as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis after the use of at least one biologic disease-modifying antirheumatic drug: analyses from the pan-European TOCERRA register collaboration. Ann Rheum Dis 2018; 77: 1276–82.
24 Gottenberg JE, Moore J, Perrotudeau E, et al. Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort study. BMJ 2019; 364: 167.
25 Davies R, Carrasco R, Foster HE, et al. Treatment prescribing patterns in patients with juvenile idiopathic arthritis (JIA): a analysis from the UK Childhood Arthritis Prospective Study (CAPS). Semin Arthritis Rheum 2016; 46: 190–95.